Trial Profile
Open-label, single-arm, phase II study of bevacizumab (AVASTIN) in combination with alternating Xeliri and Xelox as first-line treatment of patients with metastatic colorectal cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Irinotecan; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms AXOAXI
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 27 Jul 2020 Status changed from recruiting to active, no longer recruiting.
- 04 Jul 2020 Primary endpoint (Resection eligibility rate (Resectability rate)) has been met.